Skip to main content
. Author manuscript; available in PMC: 2014 Sep 12.
Published in final edited form as: Gynecol Oncol. 2009 Oct 17;116(1):61–65. doi: 10.1016/j.ygyno.2009.09.018

Table 3.

In-vitro drug assay results

Carboplatin Cisplatin Paclitaxel* Docetaxel
EDR 7.9 6.9 23.2 13.6
IDR 25.7 20.7 31.4 36.7
LDR 66.4 72.3 45.3 49.7
Cyclophos Doxil Doxorubicin Etoposide
EDR 18.5 32.4 44.6 31.9
IDR 30.3 36.4 24.6 38
LDR 51.3 31.3 30.8 30.1
Fluorouracil Gemcitabine Ifosamide Topotecan
EDR 25.3 7.9 22.4 17.2
IDR 28 10.9 20.9 32.5
LDR 46.7 81.2 56.7 50.2

Percentage is shown.

*

p<0.05 (Paclitaxel EDR vs platinum and docetaxel EDR).

Abbreviations: cyclophos, cyclophosphamide; EDR, extreme drug resistance; IDR, intermittent drug resistance; and LDR, low drug resistance.